原发性和继发性肝癌患者区域门静脉输注5-氟尿嘧啶的结果
Results of regional portal infusion of 5-fluorouracil in patients with primary and secondary liver cancer.
作者信息
Almersjö O, Gustavsson B, Hafström L
出版信息
Ann Chir Gynaecol. 1976;65(1):27-32.
The survival of 47 patients with liver malignancies treated with continuous portal infusion of fluorouracil (5-FU) has been studied. 18 of them had been treated initially by hepatic artery ligation. Total mean survival was 9.4 months. Patients treated with hepatic artery ligation + 5-FU lived longer (mean 10.8 months) than those treated with 5-FU alone (7.4 months). The survival was longer than could be expected for patients treated for primary liver cancer or for liver metastases from colo-rectal cancer, when compared with the "untreated" group. It is concluded that continuous portal infusion of 5-FU appears to prolong survival in some groups of patients with malignant liver tumours. However, the influence of "unspecific, general" therapy is difficult to evaluate.
对47例接受氟尿嘧啶（5-FU）持续门静脉输注治疗的肝脏恶性肿瘤患者的生存情况进行了研究。其中18例最初接受了肝动脉结扎治疗。总平均生存期为9.4个月。接受肝动脉结扎+5-FU治疗的患者（平均10.8个月）比单纯接受5-FU治疗的患者（7.4个月）存活时间更长。与“未治疗”组相比，该生存期长于原发性肝癌或结直肠癌肝转移患者的预期生存期。得出的结论是，持续门静脉输注5-FU似乎能延长某些组肝脏恶性肿瘤患者的生存期。然而，“非特异性、一般性”治疗的影响难以评估。
Zotero 插件